{
    "clinical_study": {
        "@rank": "164867", 
        "brief_summary": {
            "textblock": "This is an observational post-marketing study conducted in children and adults immunized\n      with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California\n      (NCKP) sites."
        }, 
        "brief_title": "Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Observation Safety", 
        "detailed_description": {
            "textblock": "Children and adults will be immunized with Q/LAIV as part of routine clinical practice at\n      Kaiser Permanente Northern California (NCKP) sites. Using existing data on healthcare\n      utilization, rates of medically attended events (MAEs) of interest will be evaluated in all\n      eligible Q/LAIV recipients who are vaccinated in the Kaiser Permanente (KP) Northern\n      California Health Care Plan during the 2013-2014 influenza season. Enrollment must include a\n      minimum of 10,000 children 2 through 8 years of age; based on previous utilization of\n      FluMist at NCKP, enrollment is expected to include approximately 80,000 children and adults\n      2 to 49 years of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. . Age 2 through 49 years at the time of vaccination (or index date for unvaccinated\n             controls)\n\n          2. . Membership in the KP Health Care Plan for at least 12 months prior to\n             vaccination/index date\n\n          3. . Continuous enrollment in KP Health Care Plan through 6 months following\n             vaccination/index date.\n\n        Exclusion Criteria:\n\n        NONE"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Children and adults 2 to 49 years of age vaccinated with Q/LAIV, TIV or no vaccine at\n        Kaiser Permenente Northern California sites."
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985997", 
            "org_study_id": "MA-VA-MEDI3250-1115"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "FluMist, Quadrivalent, Vaccine", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oakland", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94612"
                }, 
                "name": "Kaiser Permenente Northern California"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Naomi Veney", 
            "phone": "301-398-000"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Herve Caspard, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Rates of medically attended events from 0 to 3 days: hypersensitivity, seizures/convulsions", 
                "measure": "Rates of medically attended events: hypersensitivity, seizures/convulsions", 
                "safety_issue": "Yes", 
                "time_frame": "From 0-3 days"
            }, 
            {
                "description": "Rates of medically attended events from 1 to 42 days: lower respiratory tract infection, wheezing, Guillain-Barr\u00e9 syndrome, Bell's palsy, encephalitis, neuritis, vasculitis, any hospitalization and respiratory hospitalizations", 
                "measure": "Rates of medically attended events: lower respiratory tract infection, wheezing, Guillain-Barr\u00e9 syndrome, Bell's palsy, encephalitis, neuritis, vasculitis, any hospitalization and respiratory hospitalizations", 
                "safety_issue": "Yes", 
                "time_frame": "From 1 to 42 days"
            }, 
            {
                "description": "Rates of medically attended events from 1 to 180 days: narcolepsy/cataplexy", 
                "measure": "Rates of medically attended events: narcolepsy/cataplexy", 
                "safety_issue": "Yes", 
                "time_frame": "From 1 to 180 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985997"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}